Rule 3.8A

Appendix 3F

Final share buy-back notice
(*except* minimum holding buy-back)

Introduced 1/9/99. Origin: Appendices 7D and 7E. Amended 30/9/2001, 11/01/10

Information and documents given to ASX become ASX's property and may be made public.

Name of entity	ABN/ARSN
Mayne Pharma Group Limited	76 115 832 963

We (the entity) give ASX the following information.

Description of buy-back

1	Type of buy-back	On market buy-back

Details of all shares/units bought back

2	Number of shares/units bought back	Nil Between the period 25 May 2023 and 24 May 2024, the Company bought back 3,828,461 shares for a total consideration of AU$17,155,375.72 (as announced to ASX on 25 May 2024). On the same date, a further notice was filed related to Mayne Pharma's ability to buy back additional shares between 25 May 2024 and 29 November 2024. No shares were bought back between 25 May 2024 and 29 November 2024.
3	Total consideration paid or payable for the shares/units	N/A (see note above)
4	If buy-back is an on-market buy-back - highest and lowest price paid	highest price: N/A date: N/A lowest price: N/A date: N/A

+ See chapter 19 for defined terms.

Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.

or, for trusts only:

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.

2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here: ..... Date: 3 December 2024
(~~Director/~~Company secretary)

Print name: Laura Loftus

== == == == ==

+ See chapter 19 for defined terms.